Search clinical trials for: TURBUHALER

Total 128 results

Université de Sherbrooke

Completed

Activation of Brown Adipose Tissue Thermogenesis in Humans Using Formoterol Fumarate (GB10) (GB10)

Obesity | Type 2 Diabetes

Canada
Centre Hospitalier Intercommunal Creteil
AstraZeneca

Terminated

Budesonide/Formoterol Turbuhaler® Versus Terbutaline Nebulization as Reliever Therapy in Children With Moderate Asthma Exacerbation (ASTHMAFAST)

Asthma in Children

France
Cosmetique Active International

Completed

CLINICAL EFFICACY OF EMOLLIENTS IN ATOPIC DERMATITIS PATIENTS

Atopic Dermatitis

Brazil
Hat Yai Medical Education Center

Completed

As-needed Budesonide/Formoterol Turbuhaler in Stepping Down Period

Asthma

Thailand
Chiesi Farmaceutici S.p.A.

Completed

Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient (FORSYYN)

Chronic Obstructive Pulmonary Disease

China
AstraZeneca

Completed

Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.

Chronic Obstructive Pulmonary Disease (COPD)

Germany
Zambon SpA

Completed

Clinical Study to Evaluate Z7200 Pharmacokinetics Profile

Asthma

United Kingdom
Zambon SpA

Completed

A Clinical Study to Evaluate Z7200 (Budesonide/Formoterol) Pharmacokinetics Profile in Healthy Volunteers

Asthma

United Kingdom
Zambon SpA
FLUIDDA nv

Completed

Study to Compare the Effects of Z7200 And Symbicort® Turbohaler on Respiratory Imaging Parameters in Asthmatic Patients

Asthma | Asthma Chronic | Asthmatic | Asthma Bronchial

Belgium
Intech Biopharm Ltd.
Peking University People's Hospital; Beijing Friendship Hospital; The Second... and other collaborators

Completed

Clinical Equivalence of Budesonide HFA MDI Versus Budesonide Turbuhaler in Mild to Moderate Chinese Asthma Patients

Asthma

China
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Active, not recruiting

A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Asthma | Bioequivalence

Greece
Chiesi Farmaceutici S.p.A.

Completed

Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) (TRIVERSYTI)

COPD (Chronic Obstructive Pulmonary Disease)

China, Korea, Republic of, Taiwan
Pearl Therapeutics, Inc.

Completed

A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos) (KRONOS)

COPD

United States, Canada, China, Japan
GlaxoSmithKline

Completed

Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs

Pulmonary Disease, Chronic Obstructive

Netherlands, United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)

Bronchial Asthma

Austria, Poland, Ukraine
GlaxoSmithKline

Completed

Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects

Asthma

United Kingdom, Germany
University of Dundee
AstraZeneca; NHS Tayside

Completed

Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC Trial (MUSIC)

Chronic Obstructive Pulmonary Disease

United Kingdom
Istituto per la Ricerca e l'Innovazione Biomedica

Completed

The Use of an Innovative Device for Therapeutic Adherence in Pediatric Asthma

Asthma

Italy
Pearl Therapeutics, Inc.

Completed

Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®

COPD

Japan
Actavis Inc.
Teva Pharmaceuticals USA

Completed

Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants

Asthma

United States
AstraZeneca

Completed

A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma (SYGMA2)

Asthma

Germany, Spain, Thailand, Vietnam, Bulgaria, Russian Federation, Korea, Republic of, Brazil, Hungary, Peru, Philippines, New Zealand, Poland, Saudi Arabia, South Africa, Ukraine, Romania, Czechia, Slovakia, Colombia, Mexico, Sweden, Chil... and more
AstraZeneca

Completed

A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma. (SYGMA1)

Asthma

Canada, Vietnam, Russian Federation, Korea, Republic of, Brazil, Peru, China, Ukraine, South Africa, Australia, Bulgaria, Hungary, Poland, Philippines, Romania, Mexico, Chile, United Kingdom
GlaxoSmithKline

Completed

A Clinical Study Assessing Critical Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA® Dry Powder Inhaler, in Comparison to Combinations of Dry Powder Inhalers Used to Provide Triple Therapy, in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United Kingdom, Netherlands
Pearl Therapeutics, Inc.

Completed

Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD (telos)

Chronic Obstructive Pulmonary Disorder

United States, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, Czechia
AstraZeneca

Completed

Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients (SECURE2)

Chronic Obstructive Pulmonary Disease (COPD)

China
University Hospital, Bordeaux

Withdrawn

Description of the Ability to Learn How to Handle Inhaler Devices in Asthma (AUDIT)

Asthma

France
Mundipharma Research Limited

Completed

Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma

Asthma

Poland, Bulgaria, Romania, India, Hungary
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Withdrawn

Methylprednisolone Sodium Succinate in Treating Patients With Acute Graft-versus-Host Disease of the Gastrointestinal Tract

Acute Graft Versus Host Disease | Intestinal Graft Versus Host Disease

United States
Zhujiang Hospital

Unknown

Differences of Small Airways Function Between Chronic Obstructive Pulmonary Disease(COPD) and Asthma-copd Overlap(ACO)

Quality of Life | Pulmonary Disease, Chronic Obstructive | Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome | Small Airway Disease

China
Zhujiang Hospital

Unknown

Change of Lung Function After Exercise in Patients With Chronic Obstructive Pulmonary Disease

Quality of Life | Pulmonary Disease, Chronic Obstructive | Exercise | Lung Function Decreased

China
Pearl Therapeutics, Inc.

Completed

Pharmacokinetics and Safety Study of PT010 in Healthy Subjects

COPD

United States
Hamilton Health Sciences Corporation
AstraZeneca

Completed

Does Fluticasone Propionate Reduce the Late Allergic Reaction When the Drug is Given Post-allergen?

Mild Intermittent Asthma

Canada
Fundación Pública Andaluza Progreso y Salud

Completed

Errors in the Use of Turbuhaler and Spiromax Devices Patients With Asthma

Asthma

Spain
Consorzio Futuro in Ricerca

Completed

Comparative Study on Usability of Inhaler Devices in Adults With Asthma or COPD (PMC-101-APT)

Asthma | COPD

Italy
GlaxoSmithKline

Completed

Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Norway
AstraZeneca

Completed

Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease (RISE)

COPD Patients

United States, Spain, Bulgaria, Mexico, Poland, South Africa, Germany, Argentina, Chile, Czechia, Puerto Rico
GlaxoSmithKline

Completed

A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOTEROL® 400 and SYMBICORT® Forte in Adults With Asthma

Asthma

Argentina
GlaxoSmithKline

Completed

Study of Inhaler Device Attributes Investigating Critical and Overall Errors, Ease of Use, and Preference Between a Number of Inhaler Devices

Pulmonary Disease, Chronic Obstructive

United Kingdom, Netherlands
Hat Yai Medical Education Center

Completed

Efficacy of Once-daily Budesonide/Formoterol Turbuhaler 4.5/160 µg in Step Down Asthma

Asthma

Thailand
Chiesi Farmaceutici S.p.A.

Terminated

A Study in Patients With Chronic Obstructive Pulmonary Disease (FAIR) (FAIR)

Chronic Obstructive Pulmonary Disease

Netherlands
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study to Compare Absorption of Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler

Asthma

Finland
AstraZeneca

Completed

Relative Bioavailability Study to Compare Inhalation of Terbutaline Sulphate 1,5mg Via Turbuhaler M3 With Turbuhaler M2

Healthy Volunteers

United Kingdom
AstraZeneca

Completed

Comparing the Efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg Dose Levels, to Allow for a Switch From Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3

Asthma

Sweden, Netherlands, Canada
AstraZeneca

Completed

Symbicort Turbuhaler 30/60 Special Clinical Experience Investigation for Long-term Use for Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

Japan
Salzburger Landeskliniken
University Hospital Heidelberg

Completed

Inhaled Budesonide and Acute Mountain Sickness

Acute Mountain Sickness

Austria
AstraZeneca

Completed

Clinical Experience Investigation of Symbicort Turbuhaler as Maintenance Therapy and Reliever Therapy

Bronchial Asthma

Japan
AstraZeneca

Completed

Pulmicort Turbuhaler 100/200 Specific Clinical Experience Investigation (PEACE-Peds)

Bronchial Asthma

Japan
Research in Real-Life Ltd
Teva Branded Pharmaceutical Products R&D, Inc.; University of Sydney; The University... and other collaborators

Completed

Comparing Maintenance of Device Mastery With Turbohaler© vs. Spiromax© in Healthcare Professionals naïve to Both Devices (HCP-ELIOT)

Asthma
Pharmaxis

Completed

Aridol Challenge as a Tool to Predict Treatment Response to Inhaled Corticosteroids in COPD

Lung Diseases, Obstructive

Australia
AstraZeneca

Completed

Oxis 9mcg Turbuhaler Clinical Experience Investigation

Chronic Obstructive Pulmonary Disease

Japan

3

Subscribe